Glaxosmithkline Case Essay

538 Words3 Pages
Business Ethics Homework 6 20 March 2013 GlaxoSmithKline Case 1. Since 2005, GSK was hit with several severe lawsuits regarding product liability. When Andrew Witty was assigned the chief executive role of the company, post-merger, the ice of shares declined 50 percent, which harmed the company’s earnings, sales and reputation. The first ethical lapse came about when GSK was criticized for selling drugs to the public without informing its buyers of the detrimental side effects. The detrimental product was Paxil, designed to relieve depression, generated disastrous side effects such as addictive behavior and birth defects. This drug was marketed toward children, and this strategy caused a class-action lawsuit worth over $60 million. Another lawsuit occurred in 2010, when they paid over $2 billion to settle with Avandia. Then in 2011, GSK recorded a $3 billion charge to deal with litigation. These financial settlements were immense and a huge hit to the company, and directly impacted their product quality. Since the merger, GSK racked up over $5 billion dollars in lawsuits. Despite being such a lucrative industry, getting hit with such fines could drive any company’s corporate responsibility down. 2. When Glaxo Wellcome initially merged with SmithKline, immediately arose a management dilemma. Glaxo’s CEO Leschly had a stern management style that conflicted with SmithKline’s performance-based culture. Therefore, the merger hadn’t occurred until Leschly retired, and years later Garnier was named the CEO of the new GlaxoSmithKline. Garnier structure was a combination of a flexible, competitive strategy, while centralizing clinical activities. Garnier’s leadership style put GSK at the top of the industry. However, GSK’s compliance procedure conflicted with their competitive strategy. There was no positive monitoring procedure for verifying safety of product use. This

More about Glaxosmithkline Case Essay

Open Document